Drug Shows Promise for Sleep Disorder

Insomnia Watch
Published Online: Thursday, January 1, 2004
Drug Shows Promise for Sleep Disorder  

    The first large-scale study has demonstrated that eszopiclone effectively treats long-term insomnia. (Insomnia is defined as the perception of inadequate or poorquality sleep, accompanied by significant distress or impaired function. It is considered chronic if it occurs on most nights and lasts 1 month.)  

    In the 6-month, randomized, double-blind, placebo-controlled study, 788 patients aged 21 to 69 were given 3 mg of eszopiclone nightly. The study revealed that doses of the drug led to dramatic improvement in patients? ability to fall asleep and stay asleep and in the quality of their sleep, without any evidence of a loss of effect over time. Also, the results showed that sleep improvements were associated with consistent improvement in the patients? ratings of their ability to function well every day. (The findings were published in Sleep, November 1, 2003.)

Latest Articles
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Latest Issues